IXHL | Incannex Healthcare Limited Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.9600 - 2.0250
52 Week Range	0.9500 - 12.68
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	11,907
Average Volume	27,157
Shares Outstanding	17,642,832
Market Cap	34,938,100
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-03-02

Valuation
Profitability
Growth
Health
P/E Ratio	-1.46
Forward P/E Ratio	N/A
EPS	-1.36
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	Australia
Website	IXHL

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

IXHL's peers: BFRI, CPIX, EOLS, EVOK, IMCC, INCR, DLTNF, RAMMF, CVGRF, BHHKF, SPBBF, EGRX, ANIP, PAHC, DCPH, PBH, COLL, SSIC, RGC, PROC, SHPHF, PCRX, RMTI

*Chart delayed

Analyzing fundamentals for IXHL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IXHL Fundamentals page.

Watching at IXHL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IXHL Technicals page.